Skip to content

A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

A Randomized, Open-Label Superiority Trial Comparing Emtricitabine to Abacavir Within a Triple Drug Combination in Antiretroviral-Drug Naive HIV-1 Infected Patients

Status
Suspended
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00002362
Enrollment
Unknown
Registered
2001-08-31
Start date
1999-08-31
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

Dideoxynucleosides, Drug Therapy, Combination, Stavudine, Reverse Transcriptase Inhibitors, abacavir, efavirenz

Brief summary

This study will look at whether emtricitabine is as safe and effective as abacavir (ABC) when taken with stavudine (d4T) and efavirenz (EFV) in patients who have never taken anti-HIV drugs.

Detailed description

Patients are randomized to receive open-label emtricitabine or ABC in combination with stavudine and efavirenz. Viral load and CD4+ cell counts are compared at Weeks 24 and 48. Patients are followed for 48 weeks.

Interventions

DRUGAbacavir sulfate
DRUGEfavirenz
DRUGEmtricitabine
DRUGStavudine

Sponsors

Triangle Pharmaceuticals
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

You may be eligible if you: * Are HIV-positive and generally healthy. * Have a viral load of 5,000 copies/ml or more. * Have CD4 cell counts of 200 cells/mm3 or more. * Are age 18 or older. * Agree to practice sexual abstinence or use effective barrier methods of birth control (such as condoms).

Exclusion criteria

You will not be eligible if you: * Have ever taken anti-HIV drugs for 3 days or more. * Have had certain AIDS-related infections. * Have had severe diarrhea within the past 30 days. * Are unable to eat at least 1 meal a day due to nausea, vomiting, or stomach pain. * Are being treated for active tuberculosis (TB). * Are pregnant or breast-feeding. * Use illegal drugs or alcohol that make it difficult for you to take study drugs or keep clinic appointments. * Are taking certain medications, or have certain other conditions or diseases (see the technical summary for more detail).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026